Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Andrew H. Ko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0426-1753; OpenAlex author ID A5010303902, A5070411005; NIH RePORTER profile ID 6572556. Sources: funder_awards.

Their work

Papers
68 (first author 9, last author 10)
Trials
11 (principal investigator on 8)
Grants
2
Labs led
1
Collaborators
268
Papers, trials and grants by year

2003: 1 grant · 2004: 1 trial · 2005: none · 2006: 2 trials · 2007: 1 trial · 2008: 1 trial · 2009: none · 2010: 2 trials · 2011: 1 paper · 2012: 3 papers, 1 grant · 2013: 2 papers · 2014: 5 papers · 2015: 5 papers, 2 trials · 2016: 10 papers · 2017: 3 papers, 1 trial · 2018: 3 papers · 2019: 7 papers · 2020: 6 papers · 2021: 4 papers · 2022: 3 papers, 1 trial · 2023: 5 papers · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers

Papers 50 of 68

  1. RASolute 302: lessons learned and the road ahead in pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag346↗
  2. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
  3. Comprehensive Genomic Profiling for Resectable Pancreatic Cancer: The Earlier the Better? Co-author DOI 10.1200/op-25-01170↗
  4. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  5. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  6. Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. Co-author DOI 10.1002/cpt.3528↗
  7. Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer. First author DOI 10.1200/jco-25-01298↗
  8. Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic… Last author DOI 10.1200/oa-25-00099↗
  9. Hyperpolarized 13C Metabolic MRI of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jmri.29162↗
  10. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  11. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15579-0↗
  12. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… Co-author DOI 10.1093/oncolo/oyad022↗
  13. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  14. Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer. Co-author DOI 10.1200/jco.23.00222↗
  15. Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer. First author DOI 10.1200/jco.23.01895↗
  16. Maintenance Treatment for Metastatic Pancreatic Cancer: Balancing Therapeutic Intensity with Tolerable Toxicity. First author DOI 10.3390/cancers15143657↗
  17. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗
  18. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Last author DOI 10.1097/mpa.0000000000002021↗
  19. Helping Patients Understand Pancreatic Cancer Using Animated Pancreas Patient Education With Visual Formats of Learning. Co-author DOI 10.1097/mpa.0000000000002087↗
  20. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13968↗
  21. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  22. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Last author DOI 10.2217/imt-2021-0008↗
  23. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  24. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Last author DOI 10.1016/j.annonc.2019.09.004↗
  25. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Last author DOI 10.1016/j.annonc.2020.05.011↗
  26. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.07.017↗
  27. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  28. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗
  29. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.22462↗
  30. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Last author DOI 10.1007/s10689-018-0106-2↗
  31. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  32. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000620↗
  33. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001354↗
  34. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stra… First author DOI 10.1097/pas.0000000000001152↗
  35. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  36. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  37. Shifting the treatment model for resectable pancreatic cancer. Co-author DOI 10.1016/s2468-1253(18)30094-3↗
  38. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Co-author DOI 10.21037/hbsn.2018.06.02↗
  39. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. Co-author DOI 10.2214/ajr.18.19602↗
  40. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAI… Co-author DOI 10.1634/theoncologist.2017-0066↗
  41. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. First author DOI 10.21037/cco.2017.06.13↗
  42. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  43. Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope? Co-author DOI 10.1001/jamaoncol.2015.4869↗
  44. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Last author DOI 10.1002/jso.24375↗
  45. Raising the bar for the adjuvant treatment of pancreatic cancer. Co-author DOI 10.1016/s0140-6736(16)30680-8↗
  46. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitab… Last author DOI 10.1093/annonc/mdw006↗
  47. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000458↗
  48. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-15-0979↗
  49. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5561↗
  50. Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.015933↗

Trials 11

  1. A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma Principal investigator NCT05249101↗
  2. A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer Principal investigator NCT02908451↗
  3. Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer Principal investigator NCT02465983↗
  4. PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Principal investigator NCT02487277↗
  5. A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer Principal investigator NCT01025570↗
  6. Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Principal investigator NCT01222689↗
  7. Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers Principal investigator NCT00626158↗
  8. Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer Study chair NCT00429858↗
  9. Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine Study chair NCT00365144↗
  10. Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery Study chair NCT00410774↗
  11. Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer Principal investigator NCT00126633↗

Grants 2

  1. Dual Targeting of MEK and EGFR Signaling Pathways in Advanced Pancreatic Cancer R21CA149939↗
  2. Detection, Analysis and Significance of Micrometastases in Pancreatic Cancer AWARD pancan:2003-andrew-h-ko-md-detection-analysis-and-significance-of-m

Closest collaborators

The 25 strongest of 268 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Margaret A. Tempero · 24 shared papers, 2011–2024 · strength 1.87
  2. Eileen Mary O'Reilly · 11 shared papers, 2017–2026 · strength 1.62
  3. Evan Justin Walker · 7 shared papers, 2015–2023 · strength 1.08
  4. Robert A. Wolff · 11 shared papers, 2012–2026 · strength 1.00
  5. George Albert Fisher · 8 shared papers, 2015–2026 · strength 0.90
  6. Eric K. Nakakura · 9 shared papers, 2012–2026 · strength 0.75
  7. Pelin Cinar · 6 shared papers, 2014–2022 · strength 0.74
  8. Julia C. Carnevale · 5 shared papers, 2016–2022 · strength 0.69
  9. Robert H. Vonderheide · 6 shared papers, 2015–2026 · strength 0.67
  10. Mark H. O’Hara · 5 shared papers, 2020–2026 · strength 0.63
  11. Zev A. Wainberg · 5 shared papers, 2019–2026 · strength 0.61
  12. Zhen J. Wang · 5 shared papers, 2016–2024 · strength 0.56
  13. Vincent M. Chung · 6 shared papers, 2014–2026 · strength 0.56
  14. Eric Andrew Collisson · 7 shared papers, 2011–2021 · strength 0.54
  15. Mandana Kamgar · 1 shared paper, 2025 · strength 0.54
  16. Noelle K. LoConte · 6 shared papers, 2016–2026 · strength 0.50
  17. Al B. Benson · 7 shared papers, 2012–2026 · strength 0.47
  18. Elena Gabriela Chiorean · 6 shared papers, 2014–2026 · strength 0.45
  19. Lacey Padrón · 3 shared papers, 2022–2026 · strength 0.45
  20. Mary E. Dillhoff · 5 shared papers, 2017–2026 · strength 0.43
  21. Brian G. Czito · 6 shared papers, 2012–2026 · strength 0.43
  22. Mokenge Peter Malafa · 6 shared papers, 2012–2026 · strength 0.43
  23. Brian Matthew Wolpin · 6 shared papers, 2012–2026 · strength 0.43
  24. Marsha Reyngold · 3 shared papers, 2021–2026 · strength 0.42
  25. Charles M. Vollmer · 3 shared papers, 2021–2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.